dezocine and Neuralgia

Neuropathic pain (NP) is caused by diseases or dysfunction of nervous system and has a considerable negative impact on patients' quality of life. Opioid analgesics can be used for NP treatment. However, the effect of dezocine on NC remains unknown. In this study, we aimed to investigate the analgesic and intestinal effects of various doses of dezocine in rats with chronic constriction injuries (CCI). 100 rats were equally divided into 5 groups: the low (D1 group), medium (D2 group), and high (D3 group) doses of dezocine, and sham operation and model groups. The effects of dezocine on pain, analgesic effect, pain response, and tension and contraction frequencies of intestinal smooth muscles were assessed. With an increase in the dezocine dosage, the cumulative pain scores of rats decreased and analgesic effect significantly increased; mechanical withdrawal threshold (MWT) and thermal withdrawal latency (TWL) improved in varying degrees. The expression of the NP-related proteins glial fibrillary acidic protein (GFAP) and connexin 43 (Cx43) was also improved by dezocine treatment. The results of western blot and ELISA showed that IL-6, and monocyte chemotactic protein-1 (MCP-1) levels also decreased significantly with an increase in the dezocine dose, indicated that dezocine alleviated the inflammatory microenvironment. The dezocine exhibited no significant effect on the tension or contraction frequencies of intestinal smooth muscles of rats. In conclusion, the analgesic effect of dezocine on rats with CCI is dose-dependent and has little effect on the tension or contraction frequencies of intestinal smooth muscles. Our research proved the analgesic effect of dezocine in rats with CCI, and provided further insights into new therapies for NP treatment.

Topics: Analgesics; Animals; Constriction; Humans; Neuralgia; Quality of Life; Rats

To explore the analgesic effect of dizocine combined with ropivacaine on recurrent neuropathic pain in rat model of peripheral nerve compression. Rats were randomly divided into 5 groups: sham control group (S), peripheral nerve compression model group (M), dizocine group (D), ropivacaine group (R), and combined drug group (DR). Rat peripheral nerve compression model was constructed to observe the symptoms of the rats before and after surgery. Mechanical withdrawal threshold was measured on the 21st day after surgery. The electrophysiological changes of rat peripheral nerve were measured by biopotential recording system, including proximal latency, distal latency, and compound muscle action potential. The incubation period and nerve conduction velocity were further obtained. Histological changes were observed by HE staining and toluidine blue staining. Axon number and myelin damage grade were performed, and the ultrastructure was observed by transmission electron microscopy (TEM). The mechanical withdrawal threshold, nerve conduction velocity, and compound muscle action potential were effectively increased in combination group. However, the proximal latency, distal latency, and incubation period were significantly reduced. Furthermore, dizocine combined with ropivacaine can effectively reduce the degree of myelination. TEM shown that the DR group had the best therapeutic effect, and the histological appearance of the cross section was quite similar to that of the S group. Dizocine combined with ropivacaine has a significant analgesic effect in rat model of peripheral nerve compression.

Topics: Analgesics, Opioid; Anesthetics, Local; Animals; Bridged Bicyclo Compounds, Heterocyclic; Disease Models, Animal; Drug Therapy, Combination; Electrophysiological Phenomena; Male; Neuralgia; Pain Threshold; Peripheral Nerve Injuries; Rats; Rats, Wistar; Recurrence; Ropivacaine; Sciatic Nerve; Tetrahydronaphthalenes